Abstract:Objective To detect the platelet inhibition of aspirin and clopidogrel in patients after percutaneous transluminal angioplasty and stenting(PTAS) using a thromboelastograph(TEG) instrument in order to guide the individualized adjustment of anti-platelet aggregation drugs after PTAS.Methods The clinical data of 65 patients with ischemic stroke or transient ischemic attack included from Nanjing Stroke Registry Program were analyzed retrospectively.Venous blood samples were collected at day 3 after PTAS.A TEG instrument was used to detect arachidonic acid(AA)-induced inhibition rate of platelet aggregation and adenosine diphosphate(ADP) receptor-induced inhibition rate of platelet aggregation.The AA pathway and ADP receptor-induced inhibition rate of platelet aggregation,as well as the response differences of the patients between aspirin and clopidogrel therapy were compared.Results ①The inhibition rate(80±28%) of aspirin for the AA pathway was significantly higher than that(53±31%) of clopidogrel for the ADP receptor pathway(P<0.01).②Of the 65 patients,the therapeutic effects in 45(69.2%),8(12.3%),7(10.8%) and 5(7.7%) patients were good,effective,low response,and ineffective in the aspirin group,and those in 19(29.2%),14(21.5%),23(35.4%) and 9(13.8%) were good,effective,low response,and ineffective in the clopidogrel group.Of those who had a good response to aspirin,3 had no response to clopidogrel and 14 had low response to clopidogrel;of those who had a good response to clopidogrel,all responded well or effective to aspirin.Of those who had low response to clopidogrel,4 had low response to aspirin,5 had a good response to aspirin,and 14 had good results.The two efficacies had some relevance(χ2=33.311,P<0.01).③A total of 53 patients had a good+effective response to aspirin,and 12 had low response+ineffective to aspirin,while 33 and 32 patients had good+effective and low response+ineffective to clopidogrel.There was significant difference in efficacy between the two drugs(χ2m=15.042,P<0.01).Conclusion Using TEG instrument to detect the inhibition rate of platelet aggregation in patients after PTAS is beneficial to guide the development of therapeutic scheme for individualized anti-platelet aggregation in clinical practice.The inhibitory effect of platelet aggregation of aspirin after PTAS is stronger than that of clopidogrel.The patients show differential responses to aspirin and clopidogrel therapy.Some patients who have low response to clopidogrel may respond well or may be effective to aspirin.

Comparison of three platelet function tests on patients underwent percutaneous coronary intervention

A comparison of three platelet function tests in ischemic stroke patients with antiplatelet therapy

Predicting Ischaemic Events Using Platelet Reactivity in Patients Receiving Clopidogrel: Indirect Meta-Comparison among VerifyNow, Light Transmission Aggregometry and Thromboelastography

Comparing of light transmittance aggregometry and modified thrombelastograph in predicting clinical outcomes in Chinese patients undergoing coronary stenting with clopidogrel.

Predictive Value of Methods Measuring Platelet Activation for Ischemic Events in Patients Receiving Clopidogrel: A Systematic Review and Meta-analysis

Monitoring of antiplatelet therapy and changes of mean platelet volume after percutaneous coronary intervention in the patients with coronary heart disease

Comparison of VerifyNow P2Y12 and thrombelastography for assessing clopidogrel response in stroke patients in China

Platelet reactivity by thromboelastography in patients undergoing percutaneous coronary intervention

A comparative study of light transmission aggregometry and automated bedside platelet function assays in patients undergoing percutaneous coronary intervention and receiving abciximab, eptifibatide, or tirofiban

Clopidogrel versus ticagrelor in the treatment of Chinese patients undergoing percutaneous coronary intervention: effects on platelet function assessed by platelet function tests and mean platelet volume

Evaluation of the efficacy of anti-platelet aggregation drugs in patients using thromboelastograph after percutaneous transluminal angioplasty and stenting

Differences in Optimal Platelet Reactivity after Potent P2Y12 Inhibitor Treatment in Acute Coronary Syndrome Patients Undergoing Percutaneous Coronary Intervention

Residual Platelet Reactivity is Preferred over Platelet Inhibition Rate in Monitoring Antiplatelet Efficacy: Insights Using Thrombelastography

Platelet Function Tests Predicting the Efficacy and Safety of Aspirin Secondary Prevention.

Which platelet function test is suitable to monitor clopidogrel responsiveness? A pharmacokinetic analysis on the active metabolite of clopidogrel

Clinical usefulness of thrombelastograph in patients with acute coronary syndrome

Efficacy of Monitoring Platelet Function by an Automated PL-12 Analyzer During the Treatment of Acute Cerebral Infarction With Antiplatelet Medicine

Quantifying the effect of antiplatelet therapy by whole blood platelet aggregometry

Similar Inflammatory Biomarkers Reflect Different Platelet Reactivity in Percutaneous Coronary Intervention Patients Treated With Clopidogrel: A Large-Sample Study From China

Platelet function tests: a comparative review

Current situation of platelet function tests and their clinical application status during antiplatelet treatment